CareDx Completes Naveris Acquisition, Expanding Precision Oncology and Molecular Diagnostics Portfolio
CareDx, has officially completed its acquisition of Naveris, marking a significant milestone in the company’s strategy to expand beyond transplant diagnostics and strengthen its position in the rapidly growing specialty oncology market. The transaction, which was first announced in April 2026, has now closed following the fulfillment of all required closing conditions.
The acquisition brings NavDx, Naveris’ flagship blood-based molecular diagnostic test, into the CareDx portfolio. NavDx is designed to detect and monitor viral-mediated cancers, particularly human papillomavirus (HPV)-associated head and neck cancers and HPV-related anal cancers, providing clinicians with a non-invasive tool for disease monitoring from diagnosis through long-term surveillance.
By integrating Naveris’ technology and commercial operations, CareDx is expanding its precision medicine platform while broadening its reach into one of oncology’s fastest-growing diagnostic segments. Company leadership believes the acquisition will accelerate revenue growth, strengthen its molecular diagnostics portfolio, and position the company to address a significantly larger healthcare market.
Expanding Beyond Transplant Diagnostics
CareDx has built its reputation as a leader in precision diagnostics for transplant medicine, offering tests that help physicians monitor organ transplant recipients for rejection, infection, and overall graft health.
Over time, the company has steadily diversified its capabilities into adjacent areas of precision medicine, including diagnostics supporting cell therapies and hematologic malignancies.
The acquisition of Naveris represents another major step in that evolution.
Rather than focusing solely on transplant patients, CareDx now expands into specialty oncology, leveraging molecular diagnostic technologies to support cancer detection, treatment monitoring, and long-term disease surveillance.
The move reflects broader trends within healthcare, where liquid biopsy technologies and molecular diagnostics are becoming increasingly important in personalized cancer care.
Introducing NavDx
At the center of the acquisition is NavDx, Naveris’ proprietary blood-based diagnostic assay.
NavDx is specifically designed to detect circulating tumor DNA (ctDNA) associated with cancers caused by human papillomavirus (HPV).
Unlike traditional imaging or invasive tissue biopsies, NavDx analyzes blood samples to identify molecular evidence of cancer, allowing clinicians to monitor disease progression and treatment response using a minimally invasive approach.
The test supports physicians throughout multiple stages of patient care, including:
- Initial diagnosis support
- Treatment monitoring
- Detection of molecular residual disease (MRD)
- Post-treatment surveillance
- Early identification of disease recurrence
This continuous monitoring capability has become increasingly valuable as precision oncology shifts toward earlier intervention and personalized follow-up strategies.
Addressing HPV-Associated Cancers
Human papillomavirus has become one of the leading causes of several cancers worldwide.
Among the cancers currently supported by NavDx are:
- HPV-associated head and neck cancers
- HPV-related anal cancers
These cancers often require long-term surveillance following treatment because recurrence may occur months or even years after therapy.
Traditional follow-up methods frequently involve imaging studies and physical examinations.
Blood-based molecular testing provides an additional layer of information by detecting circulating tumor DNA before clinical symptoms or radiographic evidence may become apparent.
Earlier detection can potentially support more timely clinical decision-making.
First Medicare-Covered MRD Assay in Its Category
One of NavDx’s most significant achievements is its Medicare coverage.
The assay is currently recognized as the first and only Medicare-covered molecular residual disease (MRD) test for HPV-driven head and neck cancers and anal cancers.
Medicare coverage represents an important milestone for diagnostic companies because reimbursement significantly improves patient access while encouraging broader physician adoption.
Coverage also reflects growing confidence in the clinical utility of molecular diagnostics within oncology.
For CareDx, acquiring an already reimbursed diagnostic platform reduces commercialization barriers while supporting future revenue growth.
Strong Commercial Adoption
NavDx has already demonstrated substantial commercial success prior to the acquisition.
More than 130,000 tests have been reported commercially since its launch.
This level of adoption indicates increasing physician confidence in molecular surveillance for HPV-related cancers.
As clinicians continue incorporating liquid biopsy technologies into routine oncology practice, demand for blood-based monitoring solutions is expected to grow further.
The established customer base also provides CareDx with an opportunity to expand relationships with oncology providers nationwide.
Medicare Coverage Since 2023
NavDx first received Medicare coverage in 2023.
Since then, the assay has benefited from an Advanced Diagnostic Laboratory Test (ADLT) reimbursement designation.
Under this program, Medicare currently reimburses approximately $1,800 per test.
Stable reimbursement supports continued investment in laboratory infrastructure while making advanced molecular diagnostics more accessible to eligible patients.
It also creates predictable revenue streams that can support future research and commercial expansion.
Rapid Revenue Growth
Financial performance played an important role in CareDx’s acquisition decision.
During 2025, Naveris generated approximately $35 million in revenue, representing more than 100% year-over-year growth.
Such rapid expansion highlights increasing demand for precision oncology diagnostics and reflects broader adoption of liquid biopsy technologies across oncology practices.
For CareDx, the acquisition immediately adds a high-growth commercial business that complements its existing diagnostic portfolio.
Company leadership expects NavDx to contribute meaningfully to overall financial performance from the outset.
Building a Broader Precision Medicine Portfolio
With the addition of Naveris, CareDx now offers precision diagnostic services spanning multiple specialized healthcare areas.
These include:
- Solid organ transplantation
- Cell therapy monitoring
- Hematologic malignancies
- Viral-mediated cancers
- Molecular residual disease testing
- Precision oncology
The expanded portfolio enables CareDx to serve physicians across a wider range of specialties while leveraging common expertise in molecular diagnostics and genomic testing.
Addressing a Multi-Billion-Dollar Market
According to company estimates, CareDx’s addressable U.S. market has expanded substantially following the acquisition.
Previously focused primarily on transplant diagnostics, the company now targets combined markets estimated to exceed $12 billion.
Several factors are driving this market expansion, including:
- Increasing cancer incidence
- Greater adoption of molecular diagnostics
- Advances in personalized medicine
- Growth in liquid biopsy technologies
- Expansion of precision oncology programs
- Rising demand for non-invasive disease monitoring
These trends are expected to continue supporting investment across the molecular diagnostics industry.
Leveraging Commercial Expertise
CareDx believes one of its competitive advantages lies in its ability to commercialize specialized diagnostic testing.
The company has successfully introduced multiple molecular diagnostic products in transplant medicine, establishing strong relationships with healthcare providers, hospitals, and academic medical centers.
Leadership expects this commercial infrastructure to accelerate adoption of NavDx without requiring the company to build an entirely new sales platform.
Existing laboratory operations, reimbursement expertise, physician education programs, and customer support services can all contribute to expanding the assay’s market reach.
Precision Medicine Continues to Transform Oncology
The acquisition reflects broader changes occurring throughout cancer care.
Traditional oncology has relied heavily on imaging, tissue biopsies, and clinical examination for diagnosis and follow-up.
Increasingly, however, molecular diagnostics are allowing physicians to detect microscopic disease through circulating biomarkers found in blood samples.
Liquid biopsy technologies provide several potential advantages:
- Less invasive testing
- More frequent monitoring
- Earlier detection of recurrence
- Personalized treatment assessment
- Improved patient convenience
As evidence supporting these technologies continues growing, healthcare providers are integrating them into routine clinical practice.
Supporting Molecular Residual Disease Detection
One of the most promising applications of molecular diagnostics involves monitoring molecular residual disease.
MRD testing seeks to identify extremely small amounts of cancer that remain after treatment, even when imaging studies appear normal.
Detecting residual disease earlier may enable clinicians to adjust treatment plans before recurrence becomes clinically apparent.
This approach has become an increasingly important component of precision oncology across multiple cancer types.
NavDx extends these capabilities specifically to HPV-associated malignancies.
CEO Highlights Growth Strategy
CareDx President and Chief Executive Officer John Hanna described the acquisition as closely aligned with the company’s long-term business strategy.
According to Hanna, CareDx focuses on commercializing category-leading molecular biomarker tests designed for patients experiencing significant disease burdens.
Leadership believes NavDx fits that strategy exceptionally well.
The company expects its established commercial platform, operational expertise, and diagnostic infrastructure to accelerate future growth while expanding physician adoption of the assay.
Management also anticipates the acquisition becoming an immediate contributor to both revenue and long-term business performance.
The successful completion of the Naveris acquisition represents a transformative step for CareDx as it evolves into a broader precision medicine company.
By combining its established leadership in transplant diagnostics with Naveris’ innovative oncology platform, the company is expanding its ability to serve physicians and patients across multiple high-growth healthcare markets.
The addition of NavDx strengthens CareDx’s position in liquid biopsy and molecular diagnostics while providing access to a rapidly growing segment of precision oncology focused on HPV-associated cancers.
As personalized medicine continues reshaping healthcare, molecular diagnostic technologies capable of detecting disease earlier, monitoring treatment response, and identifying recurrence with greater precision are expected to play an increasingly important role.
With an expanded product portfolio, established commercial infrastructure, growing reimbursement support, and access to a U.S. market exceeding $12 billion, CareDx is well positioned to accelerate growth while advancing precision diagnostics across transplant medicine, oncology, and cell therapy.
Source link: https://www.businesswire.com/
